Johnson & Johnson's COVID-19 vaccine, on pause for 10 days, appears poised for another green light Inovio's COVID-19 vaccine funding axed as US says thanks but no thanks The next big COVID-19 bottleneck? A shortage of trained vaccine workers, experts say Shift to virtual care during COVID-19 saved 1.7M gallons of fuel, 15K tons of CO2 emissions: CommonSpirit Health NIH’s COVID-19 diagnostics contest doles out $21M for 15-minute, tabletop PCR test UPDATED Coronavirus tracker: Cigna offering employees $200 incentive for getting vaccinated Regeneron looks to inject another $330M into long-running manufacturing expansion plan: report As healthcare consumerization gains steam, organizations must balance convenient service and quality care COVID-19 tracker: U.S. pulls Inovio vaccine funding; Pfizer scores EU supply deal Featured Story | By Kevin Dunleavy With few cases of rare and severe blood clots reported over the last several days, the CDC is expected to sign off on use of the Johnson & Johnson COVID-19 vaccine today. The FDA could follow suit with a new warning attached to the shot, according to reports. read more |
| |
|---|
|
Top Stories By Annalee Armstrong U.S. officials have pulled the plug on funding a phase 3 trial for Inovio’s COVID-19 vaccine, telling the biotech that another vaccine is no longer needed as inoculations pick up around the country. read more By Fraiser Kansteiner Alongside bottlenecks around critical materials like plastic bags, COVID-19 vaccine makers are facing another, more complex shortage: people. In fact, gaps in Lonza's staff may have fueled Moderna's recent vaccine shortfalls in countries like Canada, CEO Stéphane Bancel said. read more By Dave Muoio After COVID-19 drove many medical appointments online, one of the nation's largest health systems says a year of virtual care delivery has had major benefits for the environment. read more By Andrea Park Minute Molecular’s tabletop DASH system reads inserted nasal swabs and returns results in about 15 minutes. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Fraiser Kansteiner Regeneron first unveiled plans to build a $150 million facility at its Tarrytown campus in 2015, but the company is now planning to spend another $330 million for the project, a local news outlet reports. read more By Dave Muoio COVID-19 has triggered a gold rush toward convenient virtual services. Providers and payers must now find a way to marry a tradition of high-quality care with consumer demand for easy access, stakeholders say. read more By Noah Higgins-Dunn,Fraiser Kansteiner,Eric Sagonowsky The U.S. pulled its funding for a phase 3 trial for Inovio's COVID-19 vaccine, telling the company that the country doesn't need another shot. A CDC panel of outside experts is discussing how the U.S. should use Johnson & Johnson's COVID-19 vaccine following repots of rare blood clots. And more headlines. read more |
